loading
Corvus Pharmaceuticals Inc stock is traded at $4.33, with a volume of 433.38K. It is down -2.70% in the last 24 hours and up +9.34% over the past month. Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
See More
Previous Close:
$4.45
Open:
$4.49
24h Volume:
433.38K
Relative Volume:
0.40
Market Cap:
$295.17M
Revenue:
-
Net Income/Loss:
$-27.03M
P/E Ratio:
-7.7321
EPS:
-0.56
Net Cash Flow:
$-23.97M
1W Performance:
+3.84%
1M Performance:
+9.34%
6M Performance:
-20.40%
1Y Performance:
+100.46%
1-Day Range:
Value
$4.30
$4.53
1-Week Range:
Value
$4.095
$4.53
52-Week Range:
Value
$2.13
$10.00

Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile

Name
Name
Corvus Pharmaceuticals Inc
Name
Phone
(650) 900-4520
Name
Address
863 MITTEN ROAD, BURLINGAME, CA
Name
Employee
31
Name
Twitter
Name
Next Earnings Date
2025-03-25
Name
Latest SEC Filings
Name
CRVS's Discussions on Twitter

Compare CRVS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CRVS
Corvus Pharmaceuticals Inc
4.33 321.57M 0 -27.03M -23.97M -0.56
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-02-25 Initiated H.C. Wainwright Buy
Aug-18-23 Initiated Oppenheimer Outperform
Dec-01-21 Resumed Jefferies Buy
May-27-21 Initiated Cantor Fitzgerald Overweight
Feb-10-21 Downgrade Mizuho Buy → Neutral
Sep-12-19 Initiated Mizuho Buy
May-29-19 Initiated ROTH Capital Buy
Aug-24-17 Upgrade Credit Suisse Underperform → Neutral
May-01-17 Downgrade Credit Suisse Neutral → Underperform
Apr-18-16 Initiated Credit Suisse Outperform
Apr-18-16 Initiated Guggenheim Buy
View All

Corvus Pharmaceuticals Inc Stock (CRVS) Latest News

pulisher
Jul 22, 2025

Corvus Pharmaceuticals Inc. Stock Analysis and ForecastUnstoppable investment returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Corvus Pharmaceuticals Inc. stock priceUnmatched market performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Corvus Pharmaceuticals Inc. a good long term investmentUnstoppable trading performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 20, 2025

What analysts say about Corvus Pharmaceuticals Inc. stockExplosive trading growth - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 15, 2025

Why Corvus Pharmaceuticals Inc. stock attracts strong analyst attentionReal Time Alert Service - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Corvus Pharmaceuticals Inc. stock price move sharplyDouble Your Capital Alerts - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Corvus Pharmaceuticals Inc. stock performs during market volatilityDaily Breakout Picks - Newser

Jul 15, 2025
pulisher
Jul 08, 2025

Corvus 'Undervalued' Following Atopic Dermatitis Data From Apogee, Mizuho Securities Says - MarketScreener

Jul 08, 2025
pulisher
Jul 03, 2025

Corvus Pharmaceuticals’ Promising Study on Soquelitinib for Atopic Dermatitis - TipRanks

Jul 03, 2025
pulisher
Jul 02, 2025

Corvus Pharmaceuticals: Insider Confidence and Clinical Catalysts Fueling Growth - AInvest

Jul 02, 2025
pulisher
Jul 01, 2025

OrbiMed Advisors sells Corvus Pharma (CRVS) shares worth $4.89 million By Investing.com - Investing.com Canada

Jul 01, 2025
pulisher
Jun 30, 2025

Corvus Pharmaceuticals, Inc.(NasdaqGM: CRVS) added to Russell 3000 Index - MarketScreener

Jun 30, 2025
pulisher
Jun 25, 2025

Corvus Pharmaceuticals (CRVS) Gains China Approval for Soquelitinib Trial | CRVS Stock News - GuruFocus

Jun 25, 2025
pulisher
Jun 25, 2025

Major Breakthrough: Corvus Expands Atopic Dermatitis Drug Development into Chinese Market with New Trial Approval - Stock Titan

Jun 25, 2025
pulisher
Jun 18, 2025

Financial Metrics Exploration: Understanding Corvus Pharmaceuticals Inc (CRVS) Through Ratios - DWinneX

Jun 18, 2025
pulisher
Jun 13, 2025

Corvus Pharmaceuticals: Multiple Opportunities, But Plenty Of Risk - Seeking Alpha

Jun 13, 2025
pulisher
Jun 13, 2025

Corvus Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks

Jun 13, 2025
pulisher
Jun 11, 2025

Breakthrough Systemic Sclerosis Treatment Shows Promise in Top EULAR Study | CRVS Stock News - Stock Titan

Jun 11, 2025
pulisher
Jun 11, 2025

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress - TradingView

Jun 11, 2025
pulisher
Jun 10, 2025

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Jun 10, 2025
pulisher
Jun 04, 2025

Corvus reports promising interim data on atopic dermatitis drug By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 04, 2025

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis - Nasdaq

Jun 04, 2025
pulisher
Jun 04, 2025

Corvus Pharmaceuticals Reports 'Clinically Meaningful' Itch Reduction in Latest Phase 1 Atopic Dermatitis Drug Trial Results - MarketScreener

Jun 04, 2025
pulisher
Jun 04, 2025

Corvus reports promising interim data on atopic dermatitis drug - Investing.com Australia

Jun 04, 2025
pulisher
Jun 04, 2025

Corvus Pharmaceuticals (CRVS) Reports Promising Results for Atopic Dermatitis Treatment | CRVS Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Corvus Pharmaceuticals Announces Full Data From Cohort 3 Of Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

Corvus Pharmaceuticals Announces Full Data from Cohort 3 - GlobeNewswire

Jun 04, 2025
pulisher
May 28, 2025

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times

May 28, 2025
pulisher
May 28, 2025

Exclusive: Corvus Pharmaceuticals Reveals Latest Pipeline Progress at Major Jefferies Healthcare Conference - Stock Titan

May 28, 2025
pulisher
May 20, 2025

Corvus Pharmaceuticals targets expanded soquelitinib trials with Q4 2025 results expected - MSN

May 20, 2025
pulisher
May 20, 2025

CRVS: Mizuho Adjusts Price Target for Corvus Pharma | CRVS Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Corvus Pharmaceuticals (CRVS) Target Price Adjusted Amid Positiv - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Corvus Pharmaceuticals (CRVS) Target Price Adjusted Amid Positive Drug Data | CRVS Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Mizuho cuts Corvus Pharmaceuticals target to $11, keeps rating By Investing.com - Investing.com India

May 20, 2025
pulisher
May 20, 2025

Mizuho Adjusts Price Target on Corvus Pharmaceuticals to $11 From $12, Maintains Outperform Rating - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

Mizuho cuts Corvus Pharmaceuticals target to $11, keeps rating - Investing.com

May 20, 2025
pulisher
May 13, 2025

Corvus Pharmaceuticals (NASDAQ:CRVS) Upgraded by StockNews.com to Hold Rating - Defense World

May 13, 2025
pulisher
May 12, 2025

Corvus Pharmaceuticals (CRVS) Sees Increased Investor Interest A - GuruFocus

May 12, 2025

Corvus Pharmaceuticals Inc Stock (CRVS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Cap:     |  Volume (24h):